Monopar Therapeutics acting CMO sells $111 of stock, exercises options

Acting Chief Medical Officer at Monopar Therapeutics, Patrice Rioux, sold 1 share of the company's stock and exercised options on August 26, 2026, as reported in an SEC filing. The stock sale amounted to $111, while the option exercise cost $6, totaling $117. Monopar Therapeutics' stock, currently trading at $113.94 near its 52-week high of $124.82, has seen a remarkable 216% increase over the past year.

Following the transactions, Rioux directly owns 5,065 shares of Monopar Therapeutics common stock. The exercised stock options were part of a grant made in December 2016, with vesting occurring between January and June 2017. While some analysts suggest the stock may be overvalued, investment data indicates a potential for further growth.

Monopar Therapeutics has also made significant progress in its New Drug Application (NDA) for ALXN1840, a treatment for Wilson disease, and appointed new executives to strengthen its commercial capabilities. However, some analysts have downgraded the stock, citing it as fairly valued at the current risk level.